Immunic (NASDAQ:IMUX) Research Coverage Started at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Immunic (NASDAQ:IMUX) in a research report sent to investors on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating on the stock.

Other analysts also recently issued reports about the company. Wedbush reiterated an “outperform” rating and set a $45.00 target price on shares of Immunic in a research note on Thursday, September 10th. Zacks Research raised Immunic from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Immunic in a research note on Thursday, September 10th. Roth Capital restated a “buy” rating on shares of Immunic in a research note on Tuesday, September 1st. Finally, Wall Street Zen downgraded Immunic from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. Four equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $35.43.

Immunic Stock Performance

Shares of NASDAQ IMUX opened at $7.41 on Friday. The firm’s 50 day moving average price is $11.06 and its 200-day moving average price is $12.49. The company has a market cap of $101.07 million, a PE ratio of -1.69 and a beta of 1.45. Immunic has a 52-week low of $5.06 and a 52-week high of $17.43.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.36. On average, analysts forecast that Immunic will post -3.71 earnings per share for the current fiscal year.

Institutional Trading of Immunic

A number of large investors have recently made changes to their positions in the stock. Braidwell LP purchased a new position in Immunic in the second quarter worth about $9,914,000. Avidity Partners Management LP grew its stake in shares of Immunic by 42.6% during the 1st quarter. Avidity Partners Management LP now owns 6,699,411 shares of the company’s stock valued at $7,436,000 after purchasing an additional 2,000,000 shares during the period. CTC Alternative Strategies Ltd. bought a new stake in shares of Immunic during the 1st quarter valued at about $27,000. Bank of America Corp DE grew its stake in shares of Immunic by 80,724.2% during the 1st quarter. Bank of America Corp DE now owns 143,867 shares of the company’s stock valued at $160,000 after purchasing an additional 143,689 shares during the period. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of Immunic during the 1st quarter valued at about $33,000. 51.82% of the stock is currently owned by institutional investors.

About Immunic

Immunic, Inc (NASDAQ: IMUX) is a clinical-stage biopharmaceutical company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on treatments designed to address significant unmet needs while potentially offering convenient alternatives to injectable or infusion-based therapies.

Immunic’s lead product candidate is vidofludimus calcium, formerly known as IMU-838. It is a selective oral inhibitor of dihydroorotate dehydrogenase (DHODH) being developed for multiple sclerosis, including relapsing and progressive forms of the disease.